Terms: = Thyroid cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
153 results:
1. DNA Methylation-Regulated HOXC8's Role in her2-Positive Breast cancer Function and its Contribution to Herceptin Resistance.
Xie X; Tang S; Yu Z
Discov Med; 2024 Mar; 36(182):559-570. PubMed ID: 38531796
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical characteristics and prognostic factors of breast cancer patients with tumor deposits in the ipsilateral axillary region].
Xiao JJ; Huang ML; Yan CJ; Ling R; Wei HL
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):146-154. PubMed ID: 38418189
[No Abstract] [Full Text] [Related]
3. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
4. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
[TBL] [Abstract] [Full Text] [Related]
5. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in her2-positive breast cancer.
Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of Disease-Free Survival in Breast cancer using Deep Learning with Ultrasound and Mammography: A Multicenter Study.
Han J; Hua H; Fei J; Liu J; Guo Y; Ma W; Chen J
Clin Breast Cancer; 2024 Apr; 24(3):215-226. PubMed ID: 38281863
[TBL] [Abstract] [Full Text] [Related]
7. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
Wang J; Xia YC; Tian BX; Li JT; Li HY; Dong H; Li XG; Yu H; Zhu YY; Ma J; Jiang YJ; Jin GZ
Cancer; 2024 Apr; 130(S8):1424-1434. PubMed ID: 38217532
[TBL] [Abstract] [Full Text] [Related]
8. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in her2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract] [Full Text] [Related]
9. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract] [Full Text] [Related]
10. The Association of Melanoma-Associated Antigen-C Gene With Clinicopathological Characteristics and prognosis in Breast cancer: A Systematic Review and Meta-Analysis.
Lin X; Huo J; Su H; Xu Y; Zhang F
Clin Breast Cancer; 2024 Jan; 24(1):7-16. PubMed ID: 37872029
[TBL] [Abstract] [Full Text] [Related]
11. Research Status of Systemic Adjuvant Therapy for Early Breast cancer.
Hu W; Xu D; Li N
Cancer Control; 2023; 30():10732748231209193. PubMed ID: 37864566
[TBL] [Abstract] [Full Text] [Related]
12. Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing her-2 protein expression and mRNA stability by binding to HUR.
Liu C; Lu C; Yixi L; Hong J; Dong F; Ruan S; Hu T; Zhao X
Breast Cancer Res; 2023 Oct; 25(1):124. PubMed ID: 37848981
[TBL] [Abstract] [Full Text] [Related]
13. LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein.
Cai Z; Shi Q; Li Y; Jin L; Li S; Wong LL; Wang J; Jiang X; Zhu M; Lin J; Wang Q; Yang W; Liu Y; Zhang J; Gong C; Yao H; Yao Y; Liu Q
Sci Adv; 2023 Oct; 9(40):eadi3821. PubMed ID: 37801505
[TBL] [Abstract] [Full Text] [Related]
14. Pyrotinib-based therapeutic approaches for her2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of clinicopathological characteristics and prognostic factors of early-stage human epidermal growth factor receptor 2 (her2)-low breast cancer: Compared with her2-0 breast cancer.
Wu Q; Yang F; Liu Y; Zhang H; Zhang S; Xin L; Xu L
Cancer Med; 2023 Oct; 12(19):19560-19575. PubMed ID: 37772432
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological features and prognosis of patients with her2-low breast cancer.
Yang X; Li Y; Lu X; Ren X; Hua B
BMC Cancer; 2023 Sep; 23(1):914. PubMed ID: 37770874
[TBL] [Abstract] [Full Text] [Related]
17. Clinical characteristics and prognosis of postpartum breast cancer.
Paik PS; Choi JE; Lee SW; Lee YJ; Kang YJ; Lee HJ; Bae SY;
Breast Cancer Res Treat; 2023 Nov; 202(2):275-286. PubMed ID: 37542632
[TBL] [Abstract] [Full Text] [Related]
18. prognosis difference between her2-low and her2-zero breast cancer patients: a systematic review and meta-analysis.
Li C; Yuan Q; Deng T; Xu G; Hou J; Zheng L; Wu G
Breast Cancer; 2023 Nov; 30(6):965-975. PubMed ID: 37470943
[TBL] [Abstract] [Full Text] [Related]
19. Predictive biological factors for late survival in patients with her2-positive breast cancer.
Kang YJ; Oh SJ; Bae SY; Kim EK; Lee YJ; Park EH; Jeong J; Park HK; Suh YJ; Kim YS
Sci Rep; 2023 Jul; 13(1):11008. PubMed ID: 37420033
[TBL] [Abstract] [Full Text] [Related]
20. MiR-18a-5p attenuates her2-positive breast cancer development by regulating PI3K/AKT pathway.
Liu Y; Yang H
Cancer Biol Ther; 2023 Dec; 24(1):2224512. PubMed ID: 37394766
[TBL] [Abstract] [Full Text] [Related]
[Next]
